Verisk Analytics (VRSK) has rolled out a significantly upgraded U.S. Tropical Cyclone model through its Synergy Studio cloud platform, sharpening how insurers, reinsurers, and capital markets quantify hurricane risk in a near-present climate setting.
See our latest analysis for Verisk Analytics.
The upgraded hurricane model and recent product partnerships come against a mixed backdrop for investors, with the share price at US$183.97 after a 1 day share price return of 5.13% and a 90 day share price return that has fallen 14.33%. The 1 year total shareholder return is down 41.51%, suggesting short term momentum is improving even as longer term performance remains under pressure.
If you are weighing Verisk against other data and risk focused companies, it can be helpful to widen the lens and look at 20 top founder-led companies
With Verisk trading at US$183.97, carrying an estimated 24% intrinsic discount and sitting below the average analyst target, the key question is whether investors are overlooking its risk analytics franchise or whether the stock already reflects future growth.
Most Popular Narrative: 164% Overvalued
At a last close of $183.97 versus a narrative fair value of $69.70, the most followed valuation view implies investors are paying a steep premium and treating Verisk as a cash flow franchise rather than a fast compounder.
Verisk Analytics is a regulatory-grade data toll on the US property & casualty insurance industry, monetized through ~83% subscription revenue with ~92% client retention. VRSK's narrow-moat franchise produces FCF with an unusually high degree of predictability, durable enough to justify a 15× exit multiple at a 35% margin of safety.
If you want to see what really drives that gap between the fair value and today’s price, the key ingredients are subscription heavy revenues, margin assumptions and the exit multiple according to Esteban.
Result: Fair Value of $69.70 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that thesis could be tested if subscription growth slows or if pricing power weakens, especially in the event that insurers push back on data costs.
Find out about the key risks to this Verisk Analytics narrative.
Another View: Our DCF Suggests Undervaluation
Esteban’s fair value of $69.70 presents Verisk as 164% overvalued. However, our DCF model reflects a different perspective. At a current price of $183.97 versus an estimated fair value of $242.36, Verisk appears roughly 24% undervalued. Which set of assumptions do you trust more?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Verisk Analytics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With mixed signals running through this story, it makes sense to move quickly, stress test the assumptions that matter most, and let the data guide your stance by weighing 2 key rewards and 1 important warning sign.
Ready to hunt for more investment ideas?
If this valuation debate has you thinking more broadly, now is the time to scan for other stocks that fit your style before the next move passes you by.
- Target value opportunities that combine quality with a potential price gap by checking the 48 high quality undervalued stocks.
- Prioritize resilience and capital preservation by running through the 62 resilient stocks with low risk scores.
- Spot lesser known companies with solid underpinnings before the crowd catches on by using the screener containing 22 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com